Mebendazole for Stage IV Cancer
Also known as: Vermox
Better CNS penetration than fenbendazole makes mebendazole particularly relevant for brain tumors and CNS metastases.
Mechanism of Action
Mebendazole binds β-tubulin with isoform selectivity, disrupting microtubule dynamics. It inhibits VEGF-mediated angiogenesis, modulates NF-κB, and induces apoptosis through BCL-2 family modulation. Its ability to cross the blood-brain barrier distinguishes it from fenbendazole for CNS applications.
General mechanism: Benzimidazole anthelmintic. β-tubulin binding, anti-angiogenic (VEGF), NF-κB modulation, BCL-2 family modulation. Good BBB penetration.
Current Evidence
Phase I/II trials for glioblastoma are ongoing. Preclinical evidence strong for anti-angiogenic and direct cytotoxic effects. Decades of antiparasitic safety data. Combination with temozolomide is being studied.
Clinical Status: Phase I/II for glioblastoma. Well-established safety profile from antiparasitic use.
Safety Profile
Decades of safe antiparasitic use. Hepatotoxicity monitoring at high doses. GI effects. Myelosuppression possible with prolonged use.
Key Research Questions
- Can mebendazole enhance temozolomide efficacy in glioblastoma?
- Does mebendazole's anti-angiogenic effect complement bevacizumab?
- What is the optimal dose and schedule for anti-cancer use vs. antiparasitic use?